Accumulating evidence correlates elevated RAD51 expression and HR-related function with poorer prognosis, metastasis and resistance to chemotherapy and radiotherapy in various tumour types, including PDAC, which remains a significant unmet medical need [17–19]. Here, RAD51 is linked to neoplasm.